JPS643848B2 - - Google Patents
Info
- Publication number
- JPS643848B2 JPS643848B2 JP53075570A JP7557078A JPS643848B2 JP S643848 B2 JPS643848 B2 JP S643848B2 JP 53075570 A JP53075570 A JP 53075570A JP 7557078 A JP7557078 A JP 7557078A JP S643848 B2 JPS643848 B2 JP S643848B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- calcium
- group
- firing
- insulin secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000237502 Ostreidae Species 0.000 claims description 10
- 235000020636 oyster Nutrition 0.000 claims description 9
- 238000010304 firing Methods 0.000 claims description 8
- 230000003914 insulin secretion Effects 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000011575 calcium Substances 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 229960005069 calcium Drugs 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 5
- 239000001527 calcium lactate Substances 0.000 description 5
- 229960002401 calcium lactate Drugs 0.000 description 5
- 235000011086 calcium lactate Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000548230 Crassostrea angulata Species 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- -1 silicate ion Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は新規なインシユリン分泌促進剤に関す
るものである。さらに詳しくいうと、本発明はか
き貝殻を空気を遮断した状態で高温に焼成した粉
末状焼成体からなるインシユリン分泌促進剤に関
するものである。
従来、インシユリン分泌促進剤として種々の有
機系化合物が知られているが、本発明によるよう
な無機系のものは知られていない。
本発明者は、かき貝殻の焼成体の薬理効果につ
いて種々研究を重ね、このものはすぐれたインシ
ユリン分泌促進効果を有することを見出し、本発
明を完成するに到つた。
本発明においてインシユリン分泌促進剤原料と
しては、かきの貝殻が用いられ、たとえば、マガ
キ、ナガガキ、近江ガキ、僧帽ガキ、覆瓦ガキの
貝殻が適用される。これらのかきの貝殻は、これ
をそのまま粉砕した粉末状で漢方薬として使用さ
れていているものである。
本発明の薬剤を得るには、このかき貝殻を酸素
を遮断した状態で高温に焼成して焼成体としたの
ち、微粉末に粉砕する。また、このかき貝殻は微
粉砕したのち焼成してもよい。この場合、焼成温
度としては、1600〜2000℃の温度が採用される。
また、酸素遮断下の焼成手段としては、電気炉は
真空下（約10-3mmHg以下）で操作することによ
り酸素の影響を回避することができるが、かきの
貝殻の焼成に際しては炭酸ガスの発生を伴なうの
で、電気炉に焼成ガス逸出用の排出口を設けて焼
成することにより、炉内の空気は逸出され、酸素
の影響は実質上回避される。焼成時間は30〜90
分、通常、40〜60分間程度である。
このようにして得られた焼成体は、銀色又は白
茶色を帯びた白色の微粉末であり、１ｇ中のカル
シウム含量は約530mgという非常に高いものであ
る。
実施例
原料としてのマガキのかき貝殻１Kgをガス排出
口を有する電気炉において温度1800℃で50分間加
熱焼成したのち、粉砕し、微粉末状の焼成体約
450ｇを得た。
この場合の貝殻焼成の結果は次の通りである。
強熱減量20.60％，CaO73.6％，MgO0.08％，
SiO20.65％，Al2O31.44％，Fe2O30.27％，TiO0.1
％以下、Na2O1.68％，K2O0.09％，SO32.08％，
P2O50.16％，Cl-0.08％，CO21.7％。
また、焼成体1.5ｇを水0.5に溶かした溶液の
特性は次の通りである。
PH12.5、アルカリ度45.4ミリ当量／、
Ca2+884mg／，Mg2+0.1mg／以下、Na+58
mg／，K+2.1mg／，Cl-48mg／，SO4 2-180
mg／、ケイ酸イオン（SiOとして）10mg／以
下、リン酸イオン（PO4）１mg／以下。
次に、本発明による薬剤のインシユリン分泌に
対する効果を調べるために動物実験及び臨床例に
おいて試験した。
動物実験
Wistar系雄ラツト（体重200ｇ）５匹を１群と
する以下に示す７群について、種々の食餌を与え
て飼育し、飼育６日後に動脈採血を行ない、血清
インシユリン値を測定した。また、同時に血清カ
ルシウム値をも調べた。
No.１群
副甲状腺を摘除したラツトに、低カルシウム・
ビタミンＤ欠乏食（食餌Ａ）のみを投与。
No.２群
食餌Ａに本発明の薬剤（カルシウム含量526
mg／ｇ）をカルシウムとして0.6％添加した以外
はNo.１群と同じ。
No.３群
食餌Ａに乳酸カルシウムをカルシウムとして
0.6％添加した以外はNo.１群と同じ。
No.４群
食餌Ａにワダカルシウム（クエン酸カルシウ
ム、乳酸カルシウム、リン酸カルシウムの混合
物）をカルシウムとして0.6％添加した以外はNo.
１群と同じ。
No.５群
副甲状腺を摘除しないラツトに対し、食餌Ａの
みを投与。
No.６群
普通食で飼育した以外はNo.５群と同じ。
No.７群
普通食で６日間飼育した後１日絶食せしめてか
ら屠殺。
前記した動物実験の結果を次表に示す。
The present invention relates to a novel insulin secretion promoter. More specifically, the present invention relates to an insulin secretion promoter comprising a powdered fired product obtained by firing oyster shells at a high temperature while blocking air. Conventionally, various organic compounds have been known as insulin secretion promoters, but inorganic compounds such as the one according to the present invention are not known. The present inventor has conducted various studies on the pharmacological effects of baked oyster shells, and has found that this product has an excellent insulin secretion promoting effect, and has completed the present invention. In the present invention, oyster shells are used as the raw material for the insulin secretion enhancer, and for example, shells of Japanese oysters, Japanese oysters, Omi oysters, mitral oysters, and oyster oysters are applicable. These oyster shells are ground into powder and used as Chinese medicine. In order to obtain the drug of the present invention, the oyster shell is fired at a high temperature in the absence of oxygen to form a fired product, which is then ground into a fine powder. Further, the oyster shell may be pulverized and then fired. In this case, the firing temperature is 1600 to 2000°C.
In addition, as a means of firing with oxygen cut off, electric furnaces can be operated under vacuum (approximately 10 -3 mmHg or less) to avoid the effects of oxygen, but when firing oyster shells, carbon dioxide gas is not used. Therefore, by providing an electric furnace with an outlet for escaping the firing gas and firing, the air inside the furnace can escape and the influence of oxygen can be substantially avoided. Baking time is 30-90
minutes, usually about 40 to 60 minutes. The calcined product thus obtained is a silvery or whitish-brown white fine powder, and has a very high calcium content of about 530 mg per gram. Example: 1 kg of oyster shells as a raw material was heated and fired in an electric furnace with a gas outlet at a temperature of 1800°C for 50 minutes, and then crushed to produce a finely powdered fired body.
Obtained 450g. The results of shell firing in this case are as follows. Ignition loss 20.60%, CaO73.6%, MgO0.08%,
SiO 2 0.65%, Al 2 O 3 1.44%, Fe 2 O 3 0.27%, TiO0.1
% or less, Na 2 O 1.68%, K 2 O 0.09%, SO 3 2.08%,
P2O5 0.16 %, Cl - 0.08%, CO2 1.7%. Further, the characteristics of a solution prepared by dissolving 1.5 g of the fired body in 0.5 g of water are as follows. PH12.5, alkalinity 45.4 milliequivalent/,
Ca 2+ 884mg/, Mg 2+ 0.1mg/ or less, Na + 58
mg/, K + 2.1 mg/, Cl - 48 mg/, SO 4 2- 180
mg/, silicate ion (as SiO) 10 mg/or less, phosphate ion (PO 4 ) 1 mg/or less. Next, in order to investigate the effect of the drug according to the present invention on insulin secretion, it was tested in animal experiments and clinical cases. Animal Experiment Seven groups of five male Wistar rats (body weight 200 g) as shown below were fed various diets and reared. Six days after rearing, arterial blood was collected and serum insulin levels were measured. At the same time, serum calcium levels were also examined. Group No. 1: Rats whose parathyroid glands had been removed were given low calcium and
Only vitamin D-deficient diet (diet A) was administered. No. 2 group Diet A contains the drug of the present invention (calcium content: 526
Same as Group No. 1 except that 0.6% calcium (mg/g) was added. No. 3 group: Calcium lactate is used as calcium in diet A.
Same as No. 1 group except that 0.6% was added. Group No. 4 No. 4 except that 0.6% of Wada calcium (a mixture of calcium citrate, calcium lactate, and calcium phosphate) was added to diet A.
Same as group 1. Group No. 5: Only diet A was administered to rats whose parathyroid glands were not removed. Group No. 6 Same as Group No. 5 except that they were fed normal food. Group No. 7: After being reared on normal food for 6 days, they were fasted for 1 day and then slaughtered. The results of the animal experiments described above are shown in the following table.
【表】
＊ 副甲状腺摘除ラツト
＊＊ 正常ラツト
この表に示された結果から、本発明品の場合
は、副甲状腺摘除によつて有意に低下した血清カ
ルシウム値は本発明品により改善されることがわ
かり、また、副甲状腺摘除によつて低下した血清
インシユリン値（No.１群参照）は、本発明によつ
て顕著に上昇することがわかる。
臨床実験
糖尿病患者に経口的に本発明の薬剤及び乳酸カ
ルシウムを投与し、同時にブドウ糖を負荷し、血
糖及び血中インシユリンの変化を調べた。その結
果を次に示す。なお、第２表に示した「カルシウ
ム（−）」は、乳酸カルシウムも本発明品も投与
せず、ブドウ糖だけ負荷したことを意味する。[Table] * Parathyroidectomized rats ** Normal rats From the results shown in this table, in the case of the product of the present invention, the serum calcium level that was significantly lowered by parathyroidectomy can be improved by the product of the present invention. Furthermore, it can be seen that the serum insulin level, which decreased due to parathyroidectomy (see Group No. 1), is significantly increased by the present invention. Clinical Experiment The drug of the present invention and calcium lactate were orally administered to diabetic patients, and at the same time glucose was loaded, and changes in blood sugar and blood insulin were investigated. The results are shown below. Note that "calcium (-)" shown in Table 2 means that neither calcium lactate nor the product of the present invention was administered, but only glucose was loaded.
【表】
この表に示された結果からわかるように、本発
明品は、ブドウ糖負荷後の血糖上昇の抑制及びイ
ンシユリンの分泌促進に対してすぐれた効果を示
し、その効果は乳酸カルシウムよりすぐれてい
る。[Table] As can be seen from the results shown in this table, the product of the present invention has excellent effects on suppressing blood sugar rise after glucose loading and promoting insulin secretion, and its effects are superior to that of calcium lactate. There is.
Claims (1)
した粉末状焼成体からなるインシユリン分泌促進
剤。1. An insulin secretion promoter consisting of a powdered fired product obtained by firing oyster shells at high temperatures while blocking air.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7557078A JPS552654A (en) | 1978-06-22 | 1978-06-22 | Insulin secretion accelerator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7557078A JPS552654A (en) | 1978-06-22 | 1978-06-22 | Insulin secretion accelerator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS552654A JPS552654A (en) | 1980-01-10 |
| JPS643848B2 true JPS643848B2 (en) | 1989-01-23 |
Family
ID=13579964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7557078A Granted JPS552654A (en) | 1978-06-22 | 1978-06-22 | Insulin secretion accelerator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS552654A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010168399A (en) * | 2010-04-26 | 2010-08-05 | Sonoko:Kk | Pharmaceutical for controlling elevation of blood sugar |
-
1978
- 1978-06-22 JP JP7557078A patent/JPS552654A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS552654A (en) | 1980-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KOCHAKIAN et al. | Regulation of nucleic acid synthesis by androgens | |
| SU988190A3 (en) | Process for preparing hydantnoin | |
| JPS58159421A (en) | Biologically available iron derivatives without stomach injury, manufacture and medicine | |
| JP2022527981A (en) | Recombinant lysine gene with optimized expression in plants and method for producing recombinant lysine protein using it | |
| JPS643848B2 (en) | ||
| KR100242860B1 (en) | Calcium products, materials thereof and process for preparing the same | |
| EP0308362A1 (en) | Ferrous citrate complex, process for its preparation and its pharmaceutical use | |
| Dam | The formation of coprosterol in the intestine: Possible role of dihydrocholesterol, and a method of determining dihydrocholesterol in presence of cholesterol | |
| JPS6225125B2 (en) | ||
| US2904573A (en) | Ferrous citrate complex | |
| JPS6133817B2 (en) | ||
| Perks et al. | A neurohypophyseal principle in the elasmobranch pituitary | |
| Day et al. | Effects of cecectomy, succinylsulfathiazole, and p-aminobenzoic acid on vitamin K synthesis in the intestinal tract of rats | |
| JPS61178967A (en) | Novel thiosulfanate derivative, manufacture and pharmacological composition | |
| Kobayashi et al. | Role of prostaglandin E 2 on human gastric ulcers | |
| JP3005794B2 (en) | Bone mass enhancing composition exhibiting anti-osteoporosis effect | |
| Morris et al. | Myeloma of the oesophagus | |
| WO2020052072A1 (en) | Composition for killing helicobacter pylori and inhibiting digestive tract inflammation and preparation method therefor | |
| EP1090915B1 (en) | Polymorphic B form of 3-(cyclopropylmethoxy)-4-¬-4-(methylsulfonyl)phenyl - 5,5-dimethyl-5H-furan-2-one | |
| US2309884A (en) | Processing of foods | |
| JP2571441B2 (en) | Powdered egg oil and method for producing the same | |
| US2912360A (en) | Process for obtaining intrinsic factor | |
| US1736657A (en) | Method of manufacturing dry yeast for medical and pharmaceutical purposes | |
| US230874A (en) | Pulverulent preparation of phosphoric acid | |
| US3020204A (en) | Process for preparing augmentative intrinsic factor concentrate |